Whales with a lot of money to spend have taken a noticeably bullish stance on Vertex Pharmaceuticals. Looking at options history for Vertex Pharmaceuticals (NASDAQ:VRTX) we detected 10 trades. If we ...

With the business potentially at an important milestone, we thought we'd take a closer look at Vertex, Inc.'s (NASDAQ:VERX) future prospects. Vertex, Inc., together with its subsidiaries, provides ...

If you have been eyeing Vertex Pharmaceuticals and wondering whether it is the right time to buy, sell, or simply hold tight, you are far from alone. Vertex has been on a journey, sometimes up, ...

Vertex Pharmaceuticals (NASDAQ:VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet the primary endpoint in the Phase 2 pain study, offsetting a strong quarterly ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Vertex Pharmaceuticals said Monday that ...

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment -- and that’s set to continue thanks to the company's innovation. The company recently has expanded into another area, too, and ...

On Monday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported lower-than-expected first-quarter 2025 earnings. Vertex reported first-quarter adjusted earnings per share of $4.06, down from ...

In today’s rapidly evolving AI landscape, enterprises need reliable platforms that combine powerful models with practical deployment capabilities. Google Cloud’s latest enhancements to Vertex AI and ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the company’s fifth cystic fibrosis treatment Alyftrek and its non-opioid pain relief ...